Skip to content

Search

A national prospective surveillance study of acute rheumatic fever in Australian children

Acute rheumatic fever (ARF) is an important cause of heart disease in Indigenous people of northern and central Australia.

Rheumatic Fever Follow-Up Study (RhFFUS) protocol: A cohort study investigating the significance of minor

In Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and Torres Strait Islander people with children being...

The future of acute rheumatic fever and rheumatic heart disease in Australia

Globally, ARF and RHD cause more than a quarter of a million deaths and substantial disability each year.

Glenn Pearson's dream - improving Aboriginal child health

As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story

Rapid Strep A testing unlocks missed infections, offering new path to prevent rheumatic fever

New research has revealed that molecular point-of-care testing (POCT) can significantly improve detection of Group A Streptococcal (Strep A) pharyngitis compared to laboratory culture – particularly in remote communities, where results can take up to seven days – unlocking a major opportunity to prevent rheumatic

The Kids researchers granted $5 million to prevent RHD across Pacific

A team led by Dr Joseph Kado from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and The University of Western Australia (UWA) has been awarded $5 million by the Federal Government in a major push to prevent rheumatic heart disease across the Pacific.

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study

Since 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease - streptococcal vaccine development: a national heart, lung and blood institute workshop report

Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease. 

Left ventricular remodelling in rheumatic heart disease – trends over time and implications for follow-up in childhood

Rheumatic heart disease (RHD) is the most common form of acquired heart disease worldwide. In RHD, volume loading from mitral regurgitation leads to left ventricular (LV) dilatation, increased wall stress, and ultimately LV dysfunction. Improved understanding of LV dynamics may contribute to refined timing of intervention.